SGI Powers Cancer Research at AbbVie Stemcentrx

“Our new SGI UV 300 capabilities will help us achieve major milestones sooner than predicted,” said Albert Park, senior director, Bioinformatics, AbbVie Stemcentrx. “The new SGI system is able to process larger quantities of data faster than ever and provides us with ease of management. We see significant advantages of having a single OS control our systems, including ease of use, lower power consumption and increased compute power. There’s no price tag for technology that can help discover a drug that will save millions of lives.”